Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05788965 · ClinicalTrials.gov registry record · Phase 2
Semaglutide in CFRD
A Phase 2 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT05788965 is a Phase 2 study that has completed, run by University of Minnesota. The registered enrollment target is 8 participants.
The verdict
NCT05788965, a Phase 2 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This open label, single arm pilot study, will examine the safety and tolerability of GLP-1RA semaglutide as an add-on therapy to insulin for overweight/obese adult patients with cystic fibrosis related diabetes (CFRD).
Interventions
- DRUG Semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-10-16 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05788965
The ClinicalTrials.gov registry entry for NCT05788965 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Semaglutide is the first listed.
NCT05788965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05788965 about?
NCT05788965 is a clinical study titled "Semaglutide in CFRD". This open label, single arm pilot study, will examine the safety and tolerability of GLP-1RA semaglutide as an add-on therapy to insulin for overweight/obese adult patients with cystic fibrosis related diabetes (CFRD).
What is the current status of trial NCT05788965?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2023-10-16. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT05788965?
The interventions under investigation include: Semaglutide (DRUG).
Who is sponsoring clinical trial NCT05788965?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.